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ABSTRACT
Background: Identification of clinically relevant oncogenic drivers in advanced 
cancer is critical in selecting appropriate targeted therapy. Using next-generation 
sequencing (NGS)-based clinical cancer gene assay, we performed comprehensive 
genomic profiling (CGP) of advanced cases of lung adenocarcinoma.
Methods: Formalin-fixed paraffin-embedded tumors from 51 lung adenocarcinoma 
patients whose tumors previously tested negative for EGFR/KRAS/ALK by conventional 
methods were collected, and CGP was performed via hybridization capture of 4,557 
exons from 287 cancer-related genes and 47 introns from 19 genes frequently 
rearranged in cancer.
Results: Genomic profiles of all 51 cases were obtained, with a median coverage 
of 564x and a total of 190 individual genomic alterations (GAs). GAs per specimen 
was a mean of 3.7 (range 0-10).Cancer genomes are characterized by 50% (80/190) 
non-synonymous base substitutions, 15% (29/190) insertions or deletion, and 3% 
(5/190) splice site mutation. TP53 mutation was the most common GAs (15%, 
n=29/190), followed by CDKN2A homozygous loss (5%, n=10/190), KRAS mutation 
(4%, n=8/190), EGFR mutation (4%, n=8/190) and MDM2 amplification (2%, 
n=5/190). As per NCCN guidelines, targetable GAs were identified in 16 patients 
(31%) (BRAF mutation [n=1], EGFR mutation [n=8], ERBB2 mutation [n=4], MET 
amplification [n=1], KIF5B-RET rearrangement [n=2], CCDC6-RET rearrangement 
[n=1], CD74-ROS1 rearrangement [n=1], EZR-ROS1 rearrangement [n=5], and 
SLC34A2-ROS1 rearrangement [n=1]).
Conclusion: Fifty eight percent of patients wild type by standard testing for EGFR/
KRAS/ALK have GAs identifiable by CGP that suggest benefit from target therapy. CGP 
used when standard molecular testing for NSCLC is negative can reveal additional 
avenues of benefit from targeted therapy.
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BACKGROUND
The treatment of non-small-cell lung cancer has 
been revolutionized due to development of molecularly 
targeted therapy in genomically defined subsets of 
patients. The discovery of epidermal growth factor 
receptor (EGFR) mutation [1] and anaplastic lymphoma 
kinase (ALK) gene rearrangement are classic examples 
of oncogenic genomic alterations (GAs) that confer 
sensitivity to matched targeted therapy [2]. Patients 
with EGFR or ALK gene alterations have experienced 
significant survival benefit from targeted therapy 
as compared to conventional chemotherapy [3, 4]. 
Undoubtedly, tyrosine kinase inhibitors (TKI) for 
EGFR and ALK are currently the standard of care for 
EGFR-mutant and ALK-rearranged lung cancer patients, 
respectively.
However, most lung adenocarcinomas lack an 
identifiable driver oncogene such as the above and are 
therefore still treated with conventional chemotherapy. 
Therefore, maximally identifying actionable GAs in 
advanced lung cancer patients is essential to improve 
clinical outcome. The use of comprehensive genomic 
profiling (CGP) enabled identification of oncogenic 
alterations that would previously been missed by 
conventional testing, as this provides simultaneous 
detection of alterations in multiple cancer genes with 
higher sensitivity and specificity. Collaborated efforts 
using NGS has increased the diversity and expanded 
the range of possible targetable alterations in lung 
adenocarcinomas. A recent study by the Cancer Genome 
Atlas (TCGA) revealed potential novel drivers such as 
NF1, MET, ERBB2 and RIT1 which occur in 13% of cases, 
and enriched in samples lacking an activated oncogene [5]. 
These alterations, which occurred in previously oncogene-
negative subsets, may be single-gene driver events similar 
to EGFR and ALK.
Recently, rather than sequencing the entire genome 
or exome, CGP which include genes that show frequent 
alterations in cancer were developed to save the amount 
of tissue, time and effort to perform sequencing. These 
panels use PCR capture-based NGS assay that allow deep 
targeted sequencing of genes of interest from limited 
formalin-fixed, paraffin-embedded (FFPE) specimens [6]. 
Since incorporating NGS into routine oncologic practice 
requires accurate genomic profiling in a single assay, 
clinical cancer gene test may be appropriately used for 
clinical use.
In this study, we aimed to perform CGP on tumor 
specimens from patients with lung adenocarcinomas 
who tested negative for EGFR, KRAS and ALK 
previously at our institution. Our ultimate goal was 
to identify patients who were candidates for targeted 
therapy and expand treatment choices for apparently 
“wild type” patients.
RESULTS
Patients
Clinical characteristics of patients are shown in 
Table 1. This study included 51 patients (18 males and 
33 females) with a median age of 58 years (range: 29-
77 years). All patients had adenocarcinoma histology and 
the majority of patients were never-smokers (76%, n=39). 
Twenty-five patients (49%) were stage 4 at the time of 
diagnosis. All patients had underwent EGFR/KRAS/ALK 
screening by conventional sequencing and FISH and were 
found to be triple-negative.
Genomic alterations
Tumors were sequenced with a median coverage 
of 564x and a total of 190 known and 601 unknown 
individual GAs were identified. One or more GAs were 
uncovered by CGP from 94% (n= 48/51) of patients, 
with average of 3.7 alterations (range 0-10) per patient 
(Supplementary Table S1).
Non-synonymous base substitutions comprised 
50% (80/190) of the detected alterations (Figure 1): 15% 
(29/190) were insertions or deletion, and 3% (5/190) splice 
site mutation. TP53 was the most commonly mutated 
gene (30%, n=24/80) among non-synonymous base 
substitutions, followed by KRAS (10%, n=8/80) and EGFR 
(10%, 8/80). Insertions or deletions commonly involved 
TP53 (17%, 5/29) and ERBB2 (14%, 4/29), and splice site 
mutations occurred in TP53, INPP4B, ATR, and MAP2K4. 
Gene amplification comprised 20% (39/190) of genomic 
alterations, and MDM2 amplification was identified most 
frequently (13%, 5/39). Interestingly, MDM2 amplification 
was frequently found with CDK4 amplification in 3 out of 
5 cases observed. Homozygous loss comprised 5% (10/190) 
of all genomic alterations and all 10 cases were observed 
with CDKN2A. Fusion genes were found in 7% (n=14/190) 
and most commonly involved ROS1 fusion (50%, n=7/14). 
Alterations in the PI3K/mTOR pathway such as PIK3CA 
mutation, AKT1 mutation, PIK3R2 mutation, STK11 
inactivating mutation, MTOR mutation and RICTOR 
amplification were detected in 17 cases (33%).
Of note, EGFR (n=8) and KRAS (n=8) mutations, 
which were previously not detected by conventional 
sequencing, were identified and were mutually exclusive. 
EGFR mutations were enriched in tumors from females 
(P = 0.03). Of 8 EGFR mutations, 3 were not previously 
covered by the primer in the detection kit (M137I, Y891C, 
D770A). Of 8 KRAS mutations, 2 were not previously 
covered by the primer in the detection kit (Q61H, 
K179N). Mutations in tumor suppressor genes including 
STK11 (n=4), NF1 (n=2), RB1 (n=2), CDKN2A (n=4) 
were observed. Mutations in chromatin modifying genes 
ARID1A (n=2), MLL2 (n=2) were also observed.
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Clinically relevant genomic alterations
Based on National Comprehensive Cancer Network 
(NCCN) guidelines, we identified actionable genomic 
alterations with a matched targeted agent. Sixteen patients 
(39%) had previously known driver alterations: BRAF 
mutation [n=1], EGFR mutation [n=8], ERBB2 mutation 
[n=4], MET amplification [n=1], KIF5B-RET rearrangement 
[n=2], CCDC6-RET rearrangement [n=1], CD74-ROS1 
rearrangement [n=1], EZR-ROS1 rearrangement [n=5], and 
SLC34A2-ROS1 rearrangement [n=1].
In addition, genomic alterations for which targeted 
therapy could be considered in clinical trials were 
discovered in 14 patients (27%). These include the 
following alterations and the corresponding therapy: 
Table 1: Clinicopathologic findings of patients (N=51)
N %
Gender
  Male 18 35
  Female 33 65
Age
  Median (range) 58 (29-77)
Pathology
  Adenocarcinoma 51 100
Stagea
  I 5 10
  II 8 16
  III 13 25
  IV 25 49
Smoking
  Never 39 76
  Former or current smoker 12 24
a Clinical stage at the time of initial diagnosis was determined according to the 7th American Joint Commission on Cancer 
guidelines
Figure 1: Frequency of genomic alterations identified in this study.
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NF1 mutation (MEK inhibitor, NCT01885195), KRAS 
mutation (MEK inhibitor, NCT00890825) CDKN2A 
loss and CDK4 amplification (CDK4/6 inhibitor, 
NCT01237236), MDM2 amplification (MDM2 inhibitor, 
NCT01877382) and PIK3CA mutation (PI3K inhibitor, 
NCT01570296).
Seven patients with ROS1 rearrangements were 
enrolled in an ongoing trial (NCT01964157) and 
received ceritinib, a ROS1 inhibitor. CD74-ROS1, 
EZR-ROS1, SLC34A2-ROS1 rearrangements were 
identified and detailed characterization of ROS1 
rearrangements are outlined in Figure 2. Of note, one 
patient had ROS1 gene without kinase domain fused 
with SLC34A2.
DISCUSSION
In this study, we found that 16 of 51 (31%) patients 
harbored clinically actionable alterations that were not 
previously discovered in the routine clinical testing. 
This finding indicates an important opportunity to use 
targeted therapeutic strategies which will affect overall 
survival of these patients. In fact, 7 patients with ROS1 
rearrangement received ceritinib and 6 patients showed 
objective radiologic responses.
In recent years, the treatment of lung 
adenocarcinoma has been advanced by the development 
of multiple targeted therapies against receptor 
tyrosine kinases, RAS and RAF pathways. Still, lung 
adenocarcinomas without known oncogenes are treated 
with platinum-double chemotherapy as the first-
line treatment. It is well-known that platinum-based 
chemotherapy has generated a plateau in the overall 
response rate (25-35%), time to progression (4-6 
months) and the median overall survival (8-10 months). 
Our analysis of examining oncogene-negative lung 
adenocarcinomas expands the range of possible targetable 
alterations that may be applied to patients who have no 
other options but chemotherapy. For example, there were 
16 patients with previously known driver alterations, 
and vemurafenib, crizotinib, afatinib, cabozantinib could 
be used for BRAF V600E mutation, MET amplification, 
ROS1 rearrangements, HER2 mutations and RET 
rearrangements, respectively.
A similar study was recently published which 
identified actionable GAs in lung adenocarcinomas using 
broad, hybrid, capture-bsed NGS [7]. In this study, NGS 
identified actionable GAs in 65% of tumors from never 
or light smokers deemed wild type by extensive non-NGS 
testing. Never or light smokers (≤15 pack years) were 
selected to enrich the diagnostic yield for potential drivers, 
but this approach may miss important driver oncogenes such 
as BRAF and KRAS mutations which are enriched in tumors 
from patients with a history of smoking. A recent study of 
using molecularly matched therapy in lung cancer has shown 
that patients whose genomic alterations were matched to a 
targeted therapy lived significantly longer than those who 
received non-targeted therapies [8]. In this study, Kris et 
al. identified a driver oncogene in 64% of tumors in which 
no such genomic alteration was initially found on non-
NGS testing. Discordant results between the conventional 
sequencing and CGP imply that potentially clinically 
actionable targets may not be detected from in clinical care. 
Similarly, EGFR and KRAS mutations were uncovered in 
16 (31%) patients in our study. Possible reasons for the 
discordant results are low sensitivity of detection method 
and intratumoral heterogeneity. Genomic alterations with 
low allele frequencies lead to false-negative results on 
conventional sequencing [9], and subclonal mutations may 
be heterogeneous according to biopsy sites [10].
Figure 2: Characterization of ROS1 rearrangements.
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Of note, alterations potentially predicting 
sensitivity to cyclin-dependent kinase (CDK) inhibitors 
such as CDKN2A loss, CDK4 amplification, CCND1 
amplification were common in our patients, with 21 
cases in total [11, 12]. Among these, the most frequently 
altered gene was CDKN2A homozygous loss, with 
10 events. MCL1 amplifications, which preclinical 
studies have shown to be associated with sensitivity 
to CDK inhibitors, were also found in 2 patients [13]. 
Co-amplification of CDK4 and MDM2 were noted 
in 3 patients. CDK4 is located on the band q13 of 
chromosome 12, and this region contains MDM2, which 
is often amplified together in a variety of sarcomas 
such as liposarcoma, and rhabdomyosarcoma [14]. It is 
not yet known whether co-amplification of CDK4 and 
MDM2 are predictive biomarkers of CDK inhibitors, and 
functional validation in laboratory may be warranted in 
the future.
Genomic alterations that affect the PI3K-AKT-
mTOR pathway were also frequent, with 17 cases (33%) 
identified. Although functional consequences of these 
alterations are not all clear, one patient harbored a PIK3CA 
E542K mutation, which is previously reported to activate 
the PI3K-AKT pathway and could benefit from the use of 
PI3K inhibitor [15].
Although TCGA group has identified NF1 to be 
substantially mutated in adenocarcinomas [5], there was 
none identified in our patients. Since the majority of 
patients were never-smokers, it is reasonable that NF1 
mutations are differentially enriched in transversion-high 
tumors. In addition, MET activation through exon 14 
skipping has recently been identified as unique molecular 
subtype of NSCLC [16]. In this study, we identified 
1 patient who harbored MET mutation (S163Y) with 
concurrent MET genomic amplification. It is questionable 
that this patient may show response to c-MET inhibitor 
such as crizotinib.
In conclusion, we note that more comprehensive 
genomic characterization of the tumor reveals 
actionable alterations in triple-negative lung 
adenocarcinoma patients. All patients who received 
matched targeted therapy derived clinical benefit 
showing objective responses or evidence of 
tumor shrinkage. This study highlights previously 
unappreciated genetic alterations, enabling further 
refinement in sub-classification for the improved 
personalization of lung cancer treatment.
MATERIALS AND METHODS
Patient selection
Patients with lung adenocarcinomas who visited 
Yonsei Cancer Center (Seoul, Republic of Korea) 
between 2013 and 2015 were identified. Eligible 
patients had previously underwent standard molecular 
testing for EGFR/KRAS mutation and EML4-ALK 
rearrangement, and were tested triple-negative. These 
patients were enrolled in the prescreening part of an 
ongoing phase 2 trial, “An open-label, multicenter, 
phase 2 study of LDK378 in patients with non-small 
cell lung cancer harboring ROS1-rearrangement” 
(NCT01964157). Tissue and clinical information of 
patients were collected under a protocol approved by 
the Institutional Review Board of Severance Hospital. 
All patients provided written informed consent for the 
genetic analysis.
Conventional testing for EGFR, KRAS and 
EML4-ALK
EGFR and KRAS mutations were determined by 
PNAClamp mutation detection kits (Panagene Inc., 
Daejeon, Republic of Korea). A total of 40 known 
mutations are detected in the exons 18-21 of EGFR gene, 
and a total of 14 mutations are detected in the exons 2-3 of 
KRAS gene. Break-apart fluorescent in situ hybridization 
(FISH) assays (Abbott Molecular, Inc. USA) were used 
to screen for EML4-ALK rearrangement, and positivity 
was defined as ≥ 15% of break-apart signals as described 
previously [17].
NGS-based comprehensive genomic 
profiling assay
The archived tissue samples were histologically 
reviewed by an experienced pathologist (H.S.S) and 
analyzed by CGP at Foundation Medicine. Submitted 
specimens underwent additional pathologic review to 
make sure tissue adequacy (≥ 20% tumor nuclei and ≥ 
50ng of DNA) before testing. DNA was extracted from 
FFPE samples and quantified by a Picogreen fluorescence 
assay. After DNA extraction of 50-100ng, library 
construction and hybrid capture of 4,557 exons of 287 
cancer-related genes and 47 introns of 19 genes frequently 
rearranged in cancer was performed. Hybrid capture 
libraries were sequenced to > 500x average coverage 
with >100x at >99% of exons using Illumina HiSeq 2500 
sequencer. A customized analysis pipeline was used to 
process sequencing data and genomic alterations such as 
base substitutions, short insertions and deletions, copy 
number alterations and genomic rearrangements were 
detected and reported [6].
Data collection
Medical records of all patients and radiologic 
images were reviewed to evaluate demographic and 
clinicopathologic parameters, tumor response and 
survival outcome using a predesigned data collection 
format. Never-smokers were defined as those with a 
lifetime smoking-dose less than 100 cigarettes. Tumor 
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response was assessed by a computed tomography scan in 
accordance with the Response Evaluation Criteria in Solid 
Tumors (RECIST) version 1.1 [18].
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